EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis

Gina Hetland Brinkmann, Nina Paulshus Sundlisæter, Lena Bugge Nordberg, Joseph Sexton, Eirik Ikdahl, Anna-Birgitte Aga, Désirée van der Heijde, Daniel H Solomon, Siri Lillegraven, Espen A Haavardsholm

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2026.01.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Gina Hetland Brinkmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diakonhjemmet Hospital, REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway. Electronic address: gina_hetland@hotmail…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Prednisolone, Glucocorticoids, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The objective of this paper is to examine whether patients with newly diagnosed rheumatoid arthritis (RA) can discontinue prednisolone after short-term bridging therapy. METHODS: Patients naïve to disease-modifying antirheumatic drugs with recent-onset RA in the ARCTIC (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen) trial were followed for 24 months, with initial methotrexate monotherapy and prednisolone bridging therapy (tapering doses from 15 mg to 0 over 7 weeks). We explored the proportion of patients successfully discontinuing prednisolone, defined as no prednisolone use after bridging therapy, and for at least 4 subsequent months. Discontinuation was assessed after cessation of bridging therapy at 2, 3, 6, 12, 20, and 24 months. Additionally, we examined how many patients used prednisolone continuously for ≥3 months. RESULTS: Of 230 patients, 227 started prednisolone bridging therapy and were included for analyses. At baseline, mean (SD) age was 52 (13.7) years, mean (SD) disease activity score was 3.47 (1.17), 62% patients were female, and 82% patients were anticitrullinated peptide antibody positive. After 7 weeks, 84% (191/227) had discontinued prednisolone, 89% (203/227) had discontinued at 3 months, and 95% (216/227) within 24 months. Five percent (11/227) used prednisolone at every visit. The median number of days (IQR) of prednisolone use during 2 years was 55 (48-90). Among those who discontinued after 7 weeks, 80% (152/191) did not restart prednisolone. Continuous use for at least 3 months was observed in 22%. CONCLUSIONS: In newly diagnosed patients with RA using bridging therapy when starting methotrexate, over 80% successfully discontinued prednisolone. This supports that tapering to discontinuation is achievable in most patients after short-term bridging with prednisolone, in line with current European Alliance of Associations for Rheumatology recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPrednisoloneGlucocorticoidsAntirheumatic AgentsMethotrexateHumansFemaleMiddle AgedBridge TherapyMaleTreatment InterruptionDrug Therapy, CombinationAdultDrug Administration ScheduleAdministration, OralAgedTreatment Outcome

Substanzen

PrednisoloneGlucocorticoidsAntirheumatic AgentsMethotrexate

Autor:innen und Institutionen

  • Diakonhjemmet Hospital, REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway. Electronic address: gina_hetland@hotmail.com.
  • Diakonhjemmet Hospital, REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway.
  • Diakonhjemmet Hospital, REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Diakonhjemmet Hospital, REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Brigham and Women's Hospital, Harvard Medical School, Division of Rheumatology, Inflammation and Immunity, Boston, MA, USA.

Förderung

  • Research Council of Norway

Zitieren

APA

Brinkmann, G. H., Sundlisæter, N. P., Nordberg, L. B., Sexton, J., Ikdahl, E., Aga, A. B., van der Heijde, D., Solomon, D. H., Lillegraven, S., & Haavardsholm, E. A. (2026). Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.01.003

Vancouver

Brinkmann GH, Sundlisæter NP, Nordberg LB, Sexton J, Ikdahl E, Aga AB, et al. Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.01.003

BibTeX
@article{Brinkmann2026,
  author = {Brinkmann, Gina Hetland and Sundlisæter, Nina Paulshus and Nordberg, Lena Bugge and Sexton, Joseph and Ikdahl, Eirik and Aga, Anna-Birgitte and van der Heijde, Désirée and Solomon, Daniel H and Lillegraven, Siri and Haavardsholm, Espen A},
  title = {Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.01.003}
}
Kostenlos starten →